[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-346685-105":59,"doc-detail-346685-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","pan-raf-inhibitor-exarafenib-targets-braf-class-iiiii-nsclc-and-reveals-araf-ksr1-resistance-and-combination-strategies","Pan-RAF inhibitor exarafenib targets BRAF class II/III NSCLC and reveals ARAF-KSR1 resistance and combination strategies","","Pan-RAF inhibitor exarafenib is evaluated for its ability to target BRAF class II/III mutant non-small cell lung cancer (NSCLC), where approved options are lacking. Analysis of circulating tumor DNA indicates class II and III mutations account for about 65% of BRAF-mutant NSCLC cases and class II shows poorer outcomes than class I. Mechanistic resistance studies identify rewiring to an ARAF-mediated bypass via RAS–ARAF–KSR1 complexes that sustain MAPK signaling under pan-RAF inhibition. Co-targeting RAS or MEK effectively counters this resistance and supports combination strategies for clinical testing.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/pan-raf-inhibitor-exarafenib-targets-braf-class-iiiii-nsclc-and-reveals-araf-ksr1-resistance-and-combination-strategies/346685/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/pan-raf-inhibitor-exarafenib-targets-braf-class-iiiii-nsclc-and-reveals-araf-ksr1-resistance-and-combination-strategies/346685.png","ImageObject",300,407,{"name":92,"@type":93},"Emma Wilson","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-25","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why are BRAF class II and III NSCLC cases considered an unmet therapeutic need?","Question",{"text":113,"@type":114},"No approved therapies exist for NSCLC harboring BRAF class II and III mutations, unlike therapies available for BRAF class I mutants.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What target mechanism does resistance to pan-RAF inhibition involve?",{"text":118,"@type":114},"Resistance involves rewiring to an ARAF-mediated bypass pathway, maintained by RAS-mediated ARAF-KSR1 complexes that preserve MAPK signaling despite pan-RAF inhibitor treatment.",{"name":120,"@type":111,"acceptedAnswer":121},"Which combination strategies are effective against the identified resistance mechanism?",{"text":122,"@type":114},"Co-targeting RAS or MEK inhibition is effective at countering the ARAF-KSR1 mediated resistance pathway.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},346685,1790193156,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},3848291630094,"https://eur-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","Article [https://doi.org/10.1038/s41467-026-69216-3](https://doi.org/10.1038/s41467-026-69216-3)  \nPan-RAF inhibitor exarafenib targets BRAF class II/III NSCLC and reveals ARAF-KSR1 resistance and combination strategies  \nReceived: 7 October 2025  \n\n| Accepted: 27 January 2026 |\n| --- |\n| |\n| Check for updates |\n\nTadashi Manabe 1,2,3 , Hannah C. Bergo 1,2,3, Qingtian Li1,2,3, Tim Sen Wang4, Paul Severson 4, Nichol Miller4, Catherine Lee 4, Elifnur Yay Donderici5, Nicole Zhang 5, Wei Wu 1,2,3, Yu-Ting Chou1,2,3, Daniel L. Kerr1,2,3,  \nPaul Allegakoen1,2,3, Kathryn B. Grandinetti 4, Liliana Soroceanu4,  \nRobert J. Pelham4, Eric S. Martin4, Eric A. Murphy4, Vishesh Khanna6,  \nJoel W. Neal 6, Christopher T. Chen6, Shumei Kato 7, Richard Williams4 & Trever G. Bivona 1,2,3,8   \nOncogenic BRAF mutations, including those in non-small cell lung cancer (NSCLC), are classiﬁed as Class I, II, or III. While approved therapies exist for BRAF Class I mutants, no approved therapies exist for Class II and III BRAF-mutated NSCLC. Analysis of a circulating tumor DNA database reveals Class II and III mutations comprise ~65% of BRAF-mutant NSCLC cases, with Class II patients showing worse outcomes than Class I. Exarafenib, a distinct pan-RAF inhibitor, demonstrates potent activity against BRAF Class II and III mutant preclinical models and initial clinical activity. Resistance studies reveal rewiring to an ARAFmediated bypass pathway, characterized by RAS-mediated ARAF-KSR1 complexes maintaining MAPK signaling despite pan-RAF inhibitor treatment. RAS or MEK inhibition co-targeting is effective against this resistance mechanism. This study provides preclinical rationale for clinical testing of exarafenib in BRAF Class II/III cancers and unveils RAS-mediated ARAF-KSR1 complex formation as a resistance mechanism and rational co-therapy strategies.  \nThe RAF family of serine/threonine kinases, consisting of ARAF, BRAF, and CRAF, plays a pivotal role in the mitogen-activated protein kinase (MAPK) signaling pathway by transducing signals from RAS GTPases to downstream effectors, including MEK and ERK, ultimately regulating cell proliferation, differentiation, and survival1. Under normal physiological conditions, this tightly regulated signaling cascade is essential for normal cell growth and development. However, in cancer, the MAPK pathway is frequently dysregulated, often through oncogenic mutations in RAS or RAF genes, leading to increased pathway activation and oncogenic cell growth2.  \nBRAF mutations are present in a wide range of human cancers, with varying frequency across different tumor types3. These mutations represent a critical therapeutic target, as evidenced by the transformative impact of BRAF inhibitors in melanoma and other cancers. From recent studies, these mutations can be divided into three distinct classes based on their biochemical and signaling mechanisms: Class I mutations (e.g., V600E) are often considered RAS-independent and function as monomers; Class II mutations are independent of RAS and function as homodimers; and Class III mutations depend on RAS and act through heterodimer formation4,5. While selective BRAF inhibitors  \n1Department of Medicine, University of California, San Francisco, San Francisco, CA, USA. 2Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, USA. 3Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA. 4Kinnate Biopharma, San Diego, CA, USA. 5Guardant Health, Redwood City, CA, USA. 6Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA. 7Division of Hematology and Oncology, University of California San Diego, Moores Cancer Center, La Jolla, CA, USA. 8Chan-Zuckerberg Biohub, San Francisco, CA, USA. e-mail: [tadashi.manabe@ucsf.edu](tadashi.manabe@ucsf.edu); [trever.bivona@ucsf.edu](trever.bivona@ucsf.edu)  \nhave transformed the treatment ","cbCaijyiW8Yg4BcZ","https://ap.wps.com/l/cbCaijyiW8Yg4BcZ","pdf",5283510,26,"English","# Overview\n## Therapeutic gap for BRAF class II/III NSCLC\n## Exarafenib activity and resistance mechanism\n# RAF/MAPK pathway background\n## RAF family function in MAPK signaling\n## BRAF mutation classes\n# BRAF mutations in NSCLC and unmet needs\n## Frequency and challenges of tissue-based profiling\n## Liquid biopsy databases for mutation prevalence","[{\"question\":\"Why are BRAF class II and III NSCLC cases considered an unmet therapeutic need?\",\"answer\":\"No approved therapies exist for NSCLC harboring BRAF class II and III mutations, unlike therapies available for BRAF class I mutants.\"},{\"question\":\"What target mechanism does resistance to pan-RAF inhibition involve?\",\"answer\":\"Resistance involves rewiring to an ARAF-mediated bypass pathway, maintained by RAS-mediated ARAF-KSR1 complexes that preserve MAPK signaling despite pan-RAF inhibitor treatment.\"},{\"question\":\"Which combination strategies are effective against the identified resistance mechanism?\",\"answer\":\"Co-targeting RAS or MEK inhibition is effective at countering the ARAF-KSR1 mediated resistance pathway.\"}]","Pan-RAF inhibitor exarafenib targets BRAF class II/III NSCLC and reveals ARAF-KSR1 resistance and combination strategies | PDF",1790062417,66,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6343ae1459e2813e4fc83e8837a29b96.webp",983,1305,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/02702c6f2fe77337d872558a54c022a4.webp",982,1304,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8cb9b040faa542501828844957e90ab4.webp",981,1303,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/43fb9a87fd80366cd35977bd40e71e25.webp",980,1301]